21 March 2017 - British Columbia also broadens access for patients with less advanced disease who have other health conditions.
Gilead Sciences Canada today announced, effective 21 March 2017 , British Columbia will provide public access to Epclusa (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection.
This listing will support patients to access curative therapy, and will advance Canada's efforts to achieving its World Health Organization commitment to eliminate hepatitis C by 2030.